Serum and urinary metabonomic study of human osteosarcoma.

Osteosarcoma (OS) is the most common malignant bone tumor found in children. Currently, researchers have focused on protein and gene levels, while the associated metabolic variations have been poorly understood. In this study, we used a gas chromatography mass spectrometry approach and profiled small-molecule metabolites in serum and urine of 24 OS patients, 19 benign bone tumor patients, and 32 healthy controls, to determine whether there are significant alterations associated with carcinogenesis. The metabonomic results demonstrate clear intergroup separations between healthy control subjects and bone tumor patients in the orthogonal partial least-squares-discriminant analysis (OPLS-DA) models. Differential metabolites identified from the metabonomic analysis suggest a disrupted energy metabolism in OS patients, as characterized by significantly down-regulated TCA cycle and glycolysis, down-regulated lipid metabolism, dysregulated sugar levels, and up-regulated amino acid metabolism. Additionally, an increased activity of glutathione metabolism, and increased polyamine metabolism also contributed to a characteristic metabolic signature of OS patients.

[1]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. , 2003, Cancer genetics and cytogenetics.

[2]  M. S. van der Knaap,et al.  Evaluation of pentitol metabolism in mammalian tissues provides new insight into disorders of human sugar metabolism. , 2004, Molecular genetics and metabolism.

[3]  Liping Zhao,et al.  Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. , 2007, Journal of proteome research.

[4]  Yusuke Nakamura,et al.  Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma , 1989, Nature.

[5]  I. Wilson,et al.  Effect of diet on the urinary excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[7]  Y. Yoneda,et al.  Pharmacological topics of bone metabolism: glutamate as a signal mediator in bone. , 2008, Journal of pharmacological sciences.

[8]  A. Uchida,et al.  Induction of apoptotic cell death in three human osteosarcoma cell lines by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP). , 1997, Anticancer research.

[9]  Yusuke Nakamura,et al.  Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. , 2004, International journal of oncology.

[10]  G. Tremblay,et al.  The biochemistry and toxicology of benzoic acid metabolism and its relationship to the elimination of waste nitrogen. , 1993, Pharmacology & therapeutics.

[11]  P. Moughan,et al.  Long-Chain Polyunsaturated Fatty Acids and the Regulation of Bone Metabolism , 2007, Experimental biology and medicine.

[12]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[13]  A. Llombart‐Bosch,et al.  Deregulation of the G1 to S-Phase Cell Cycle Checkpoint Is Involved in the Pathogenesis of Human Osteosarcoma , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[14]  P. Gout,et al.  The x  c− cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases , 2008, Journal of cellular physiology.

[15]  E. Gerner,et al.  Polyamine-mediated post-transcriptional regulation of COX-2. , 2002, Biochimie.

[16]  王林,et al.  Orphanet , 2011 .

[17]  Johan Trygg,et al.  High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. , 2005, Analytical chemistry.

[18]  J. van der Greef,et al.  Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. , 2007, British journal of clinical pharmacology.

[19]  Ping Liu,et al.  Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. , 2006, Journal of proteome research.

[20]  I. Wilson,et al.  Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. , 2007, Journal of proteome research.

[21]  A. Patiño-García,et al.  Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. , 2009, Journal of proteome research.

[22]  D. W. Abbott,et al.  Finkel-Biskis-Reilly Mouse Osteosarcoma Virus v-fosInhibits the Cellular Response to Ionizing Radiation in a Myristoylation-dependent Manner* , 1997, The Journal of Biological Chemistry.

[23]  Tianlu Chen,et al.  Urinary metabonomic study on colorectal cancer. , 2010, Journal of proteome research.

[24]  Kyoungmi Kim,et al.  Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery*S , 2009, Molecular & Cellular Proteomics.

[25]  H. Heinzl,et al.  Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. , 1999, Clinical orthopaedics and related research.

[26]  R. Dziak,et al.  Tumor necrosis factor alpha stimulates arachidonic acid metabolism in human osteoblastic osteosarcomal cells. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[27]  Mariusz Kowalczyk,et al.  A strategy for identifying differences in large series of metabolomic samples analyzed by GC/MS. , 2004, Analytical chemistry.